American Society of Hirudotherapy

New therapeutic options in DVT prophylaxis

Review published in Orthopedics (2000)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentClinical LiteratureWille-Jørgensen P et al. · Orthopedics, 2000

Abstract

In the absence of prophylaxis, elective orthopedic surgery is associated with a high risk of venous thromboembolic events that are responsible for substantial morbidity and mortality. Despite the publication of articles questioning the significance of fatal pulmonary embolism (PE) following elective hip replacement, recent reports support the need for effective thromboprophylaxis in this indication. These reports also provide evidence of a significant reduction in fatal PE and overall mortality provided by treatment with low-molecular-weight heparin (LMWH), compared with unfractionated heparin. Even with the most effective prophylaxis currently available, however, deep vein thrombosis still develops in a minority of high-risk patients, indicating a need for improved therapies. Desirudin, a novel recombinant hirudin and direct thrombin inhibitor, has been shown to provide more effective prophylaxis than the most widely used LMWH, enoxaparin, in orthopedic surgery patients with multiple thromboembolic risk factors. This benefit was not associated with any increase in bleeding. Regional anesthesia and use of graduated compression stockings may provide additional independent reductions in thromboembolic risk in elective orthopedic surgery.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnesthesia, ConductionAnticoagulantsBandagesChondroitin SulfatesDermatan SulfateDrug CombinationsHeparin, Low-Molecular-WeightHeparan SulfateHirudin TherapyHirudinsHumansLogistic ModelsPostoperative ComplicationsPulmonary EmbolismRecombinant ProteinsRisk FactorsVenous Thrombosis

Summary

This review reports that desirudin, a recombinant hirudin, provided more effective thromboprophylaxis than enoxaparin in orthopedic surgery patients with multiple thromboembolic risk factors, without increasing bleeding. Regional anesthesia and compression stockings may further reduce thromboembolic risk.

Why This Matters for Hirudotherapy

This article examines prophylaxis against venous thromboembolism in elective orthopedic surgery, discussing anticoagulant options including LMWH and desirudin, described in the abstract as 'a novel recombinant hirudin and direct thrombin inhibitor.' The abstract reports that desirudin provided more effective prophylaxis than enoxaparin in orthopedic surgery patients with multiple thromboembolic risk factors, without increased bleeding. Desirudin is a recombinant hirudin derivative (Graetz et al., 2011); hirudin is the anticoagulant of the medicinal leech. This paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Wille-Jørgensen P. New therapeutic options in DVT prophylaxis. Orthopedics. 2000;23(6 Suppl):s639-42. PMID: 10875428

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.